logo-loader
viewNewron Pharmaceuticals, S.p.A.

Newron Pharmaceuticals focusing on treating Rett syndrome with drug acquired from Merck

Newron Pharmaceuticals SpA (SIX:NWRN) CEO Stefan Weber sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Italian company’s flagship drug xadago has received marketing authorization to treat Parkinson’s disease in the EU, Switzerland, the US, Australia, Canada, Brazil, and Colombia and is commercialized by Newron’s partner Zambon.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 6 hours ago

2 min read